Skip to main content
Clinical Trials/NCT00182507
NCT00182507CompletedPhase 4

A 12-Week, Double-Blind Trial of Olanzapine and Placebo in the Treatment of Trichotillomania

Hamilton Health Sciences Corporation1 site in 1 country34 target enrollmentStarted: June 1, 2000Last updated:
Conditions
Drugs

Trial Snapshot

Phase
Phase 4
Status
Completed
Enrollment
34
Locations
1
Primary Endpoint
Clinical Global Impression (CGI)-Improvement Scale ≤ 2

Study Overview

Brief Summary

Trichotillomania (TTM) or hair-pulling has been considered as part of the obsessive compulsive disorder (OCD) spectrum, although treatment with OCD medications has largely been unsuccessful. Tics/Tourrettes' Syndrome (TS) is a disorder, which appears to be related to TTM, but is treated with a different class of medications than used in OCD, namely antipsychotics such as olanzapine. This is a study of the safety and efficacy of olanzapine in the treatment of hair pulling.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •primary DSM-IV trichotillomania; CGI-Severity ≥ 4

Exclusion Criteria

  • •Any other Axis I primary diagnosis; CGI-S < 4; current comorbid: OCD, MDD, alcohol or substance abuse; lifetime hx of: schizophrenia, bipolar affective disorder or dementia; current pregnancy/lactation; current suicidality or homicidality; major medical problems or clinically unstable medical disease; hx of: seizures, stroke or head trauma; prior use of neuroleptics

Outcomes

Primary Outcomes

Clinical Global Impression (CGI)-Improvement Scale ≤ 2

Secondary Outcomes

  • CGI-Severity Scale, Mean change from baseline in: Yale-Brown Obsessive Compulsive Scale for TTM, the Massachusetts General Hospital Hair Pulling Scale

Investigators

Sponsor Class
Other

Study Sites (1)

Loading locations...

Similar Trials